<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048100</url>
  </required_header>
  <id_info>
    <org_study_id>ID00-034</org_study_id>
    <nct_id>NCT00048100</nct_id>
  </id_info>
  <brief_title>Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes</brief_title>
  <official_title>Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

        1. Determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute
           leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell
           transplants.

        2. Quantitate the alloreactivity of DC/ADL and circulating immune effector cells in
           patients after infusion.

        3. Assess efficacy of acute myelogenous leukemia (AML) or Chronic Myelogenous Leukemia in
           Blastic Crisis (CML-BC) derived dendritic cells and activated lymphocytes in promoting
           and sustaining remission in patients with relapse after allo-BMT or stem cell
           transplant.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual.
  </why_stopped>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Toxicity Levels</measure>
    <time_frame>From stem cell transplant baseline to 30 plus days post transplant.</time_frame>
    <description>Participant toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell transplants.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <arm_group>
    <arm_group_label>Apheresis + Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Skin biopsy &amp; either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Apheresis</intervention_name>
    <description>Apheresis for T-Cell collection</description>
    <arm_group_label>Apheresis + Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).</description>
    <arm_group_label>Apheresis + Transplant</arm_group_label>
    <other_name>SCT</other_name>
    <other_name>Stem Cell Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML (any type except M3) or CIVIL in blast crisis with greater than or equal to 20%
             bone marrow blasts at the time of related donor marrow or stem cell transplantation or
             at relapse post transplant.

          -  Willing to undergo a skin biopsy and either a leukodepletion apheresis or an
             additional marrow aspiration.

          -  Stem cell or marrow donor willing to have apheresis for T-Cell collection.

          -  Written voluntary informed consent must be obtained from patient and donor.

        Exclusion Criteria:

          -  Medical, social or psychologic factors which would prevent the patient from receiving
             or cooperating with the full course of therapy or understanding the informed consent
             procedure.

          -  AML French-American-British (FAB) subtype M3.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth J. Shpall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2002</study_first_submitted>
  <study_first_submitted_qc>October 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2002</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dendritic cells</keyword>
  <keyword>Lymphocytes</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

